A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2022-08-02
AEs
3
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-10 (study day 151); relationship: N
mild
assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-01-15 (study day 156); relationship: not assessed
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-25 (study day 197); relationship: Y
Data queries
No data queries.